v3.25.2
Product Sales year-on-year analysis: Q2 2025 (Tables)
6 Months Ended
Jun. 30, 2025
Product Sales year-on-year analysis: Q2 2025  
Product Sales year-on-year analysis: Q2 2025

World

US

Emerging Markets

Europe

Established RoW

For the half year ended 30 June

Change

Change

Change

Change

Change

    

$m

    

Act %

    

CER %

    

$m

    

Act %

    

$m

    

Act %

    

CER %

    

$m

    

Act %

    

CER %

    

$m

    

Act %

    

CER %

Tagrisso

 

1,810

13

12

761

16

489

13

15

351

8

4

209

9

5

Imfinzi

 

1,455

27

26

844

36

152

31

35

285

26

21

174

(5)

(8)

Calquence

872

10

10

583

5

49

36

43

198

19

14

42

27

28

Lynparza

 

838

13

11

378

18

162

6

7

229

11

7

69

5

2

Enhertu

230

81

82

156

n/m

n/m

51

63

56

23

24

28

Zoladex

284

4

5

4

(8)

219

9

11

38

(9)

(13)

23

(9)

(11)

Truqap

 

170

84

84

142

57

6

n/m

n/m

14

n/m

n/m

8

n/m

n/m

Imjudo

89

20

18

57

17

7

93

84

12

39

35

13

(4)

Other Oncology

 

106

(12)

(13)

1

(76)

70

(11)

(10)

5

(27)

(30)

30

(5)

Oncology

 

5,854

18

17

2,770

20

1,310

19

22

1,183

17

12

591

5

2

Farxiga

2,150

11

10

420

6

859

13

15

765

13

8

106

3

(1)

Crestor

 

319

9

9

12

3

275

17

18

n/m

n/m

32

(10)

(13)

Brilinta

215

(37)

(38)

99

(48)

63

(20)

(20)

51

(26)

(29)

2

(46)

(39)

Seloken

 

148

(2)

1

n/m

143

(2)

4

4

11

1

(5)

(3)

Lokelma

 

175

29

27

75

18

33

52

54

30

33

29

37

30

24

roxadustat

 

72

(18)

(18)

72

(18)

(18)

Wainua

44

n/m

n/m

43

n/m

1

Other CVRM

 

138

(27)

(28)

16

(73)

67

24

24

38

(35)

(37)

17

(8)

(12)

CVRM

 

3,261

3

3

665

(10)

1,512

9

11

889

5

1

195

2

(2)

Symbicort

 

715

(1)

(1)

319

7

168

(15)

(14)

137

(5)

(8)

91

11

11

Fasenra

 

502

19

18

307

14

26

33

36

125

27

22

44

20

18

Breztri

283

21

20

147

22

65

7

8

46

32

27

25

30

28

Tezspire

112

97

91

9

n/m

n/m

72

n/m

n/m

31

60

55

Pulmicort

 

106

(32)

(32)

1

(58)

81

(35)

(36)

15

(14)

(18)

9

2

2

Saphnelo

167

49

48

145

44

4

n/m

n/m

12

n/m

n/m

6

41

31

Airsupra

 

42

n/m

n/m

42

n/m

n/m

n/m

Other R&I

 

61

(23)

(24)

16

(35)

28

(25)

(25)

15

2

(3)

2

(8)

(7)

R&I

 

1,988

11

10

977

18

381

(14)

(13)

422

21

16

208

20

19

Beyfortus

98

n/m

n/m

73

n/m

24

n/m

n/m

1

34

27

Synagis

49

(39)

(37)

n/m

38

(7)

(1)

n/m

n/m

11

(68)

(69)

FluMist

10

n/m

n/m

n/m

n/m

n/m

10

Other V&I

n/m

n/m

n/m

n/m

n/m

n/m

V&I

 

157

40

42

73

n/m

38

(6)

(1)

24

n/m

n/m

22

(39)

(40)

Ultomiris

1,177

25

23

667

21

61

76

86

270

29

24

179

18

12

Soliris

 

530

(24)

(22)

280

(30)

159

23

38

56

(52)

(54)

35

(37)

(38)

Strensiq

395

16

15

319

12

16

65

58

31

30

26

29

27

21

Koselugo

 

137

20

18

52

(5)

36

51

50

37

42

37

12

28

22

Other Rare Disease

55

16

14

28

13

6

7

4

18

20

16

3

37

32

Rare Disease

2,294

7

7

1,346

3

278

37

48

412

5

1

258

7

2

Nexium

198

(10)

(9)

18

(30)

157

7

9

6

(49)

(55)

17

(52)

(51)

Other

43

(10)

(11)

3

12

29

(12)

(11)

10

(12)

(18)

1

4

(3)

Other Medicines

241

(10)

(9)

21

(26)

186

4

5

16

(32)

(38)

18

(50)

(50)

Total Medicines

 

13,795

11

10

5,852

12

3,705

11

13

2,946

12

8

1,292

4

1